Halozyme Therapeutics Inc (HALO)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	281,594	253,908	233,705	181,636	202,129	211,197	366,150	434,923	402,710	409,104	228,724	163,083	129,085	21,524	-39,698	-80,139	-72,240	-39,969	-42,804	-51,073
Total assets	US$ in thousands	1,733,270	1,892,660	1,810,440	1,699,450	1,841,510	1,864,540	1,781,390	1,162,250	1,104,430	1,185,420	1,025,860	966,582	579,924	524,029	526,997	492,353	565,874	370,356	417,830	429,109
ROA		16.25%	13.42%	12.91%	10.69%	10.98%	11.33%	20.55%	37.42%	36.46%	34.51%	22.30%	16.87%	22.26%	4.11%	-7.53%	-16.28%	-12.77%	-10.79%	-10.24%	-11.90%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $281,594K ÷ $1,733,270K
= 16.25%

Halozyme Therapeutics Inc.'s return on assets (ROA) has shown some fluctuations over the past eight quarters, ranging from 10.69% to 37.42%. It is evident that the company experienced a significant decrease in ROA between Q1 and Q2 of 2022, with the ratio dropping from 37.42% to 20.55%. The ROA then continued to decline in subsequent quarters before showing an improvement in Q4 2023, reaching 16.25%.

The overall trend indicates that Halozyme Therapeutics Inc.'s ability to generate profits from its assets has been somewhat unstable over the given period. It is recommended for investors and stakeholders to further investigate the reasons behind these fluctuations in ROA and assess the company's operational efficiency and profitability in order to make informed decisions.